{"denoms":[{"counts":[{"groupId":"BG000","value":"230"},{"groupId":"BG001","value":"115"},{"groupId":"BG002","value":"345"}],"units":"Participants"}],"groups":[{"description":"Patients received Afatinib monotherapy 40 mg film-coated tablets orally once daily.","id":"BG000","title":"Afatinib 40 mg"},{"description":"Patients received Pemetrexed 500 mg/m\\^2 lyophilised powder as intravenous infusion after Cisplatin 75 mg/m\\^2 solution for infusion as intravenous infusion on Day 1 of each 21-day treatment course up to 6 cycles.","id":"BG001","title":"Pemetrexed/Cisplatin Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.1","value":"60.5"},{"groupId":"BG001","spread":"10.0","value":"59.9"},{"groupId":"BG002","spread":"10.1","value":"60.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"147"},{"groupId":"BG001","value":"77"},{"groupId":"BG002","value":"224"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"121"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"166"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"249"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"96"}]}],"title":"Non-Asian"}],"description":"Race (Asian/non-Asian) was a stratification factor.","paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"138"}]}],"title":"EGFR mutation category: L858R"},{"categories":[{"measurements":[{"groupId":"BG000","value":"112"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"169"}]}],"title":"EGFR mutation category: Deletion Exon 19"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"38"}]}],"title":"EGFR mutation category: Other"}],"description":"EGFR mutation group (L858R/Deletion Exon 19/Other) was a stratification factor.","paramType":"NUMBER","title":"Epidermal Growth Factor Receptor (EGFR) mutation group","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"92"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"133"}]}],"title":"ECOG PS 0 (baseline)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"211"}]}],"title":"ECOG PS 1 (baseline)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"ECOG PS 2 (baseline)"}],"description":"ECOG PS measured on 6 point scale to assess participant's performance status. 0=Fully active, able to carry on all pre-disease activities without restriction.\n\n1. Restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work.\n2. Ambulatory (\\>50 percent of waking hours), capable of all self-care, unable to carry out any work activities.\n3. Capable of only limited self-care, confined to bed or chair more than 50 percent of waking hours.\n4. Completely disabled, cannot carry on any self-care, totally confined to bed or chair.\n5. Dead.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)","unitOfMeasure":"Participants"}],"populationDescription":"Randomised Set (RS): The randomised set includes all patients who were randomised to receive treatment, whether treated or not."}